Assessing the clinical use of clear cell renal cell carcinoma molecular subtypes identified by RNA expression analysis1These authors contributed equally to the writing of this article.

Jeanette E Eckel-Passow, Daniel A. Igel, Daniel J. Serie, Richard W Joseph, Thai H Ho, John C. Cheville, Alexander Parker

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Objectives: To evaluate the clinical use of recently published RNA-based molecular subtyping algorithms. Patients who undergo surgery for clinically localized clear cell renal cell carcinoma can experience very different outcomes, representing a longstanding challenge for the practicing urologist. Two recent publications suggest that molecular subtyping based on the expression of large panels of genes can help clinically localized clear cell renal cell carcinoma prognostication; however, the analyses was not adjusted for routinely collected clinicopathologic indices. Methods and materials: We obtained level 3 RNA-seq RPKM data and corresponding clinicopathologic features from The Cancer Genome Atlas (TCGA) and assigned patients to the TCGA subtypes as well as to the ccA/ccB subtypes. To determine the prognostic ability of molecular subtyping after adjusting for variables that are collected as routine medical care, we used Cox models and adjusted for the composite Mayo stage, size, grade, and necrosis (SSIGN) score. Results: Both the TCGA and the ccA/ccB subtypes are significantly associated with tumor size, category, grade, and presence of necrosis. The association of these subtypes with overall survival is markedly attenuated following adjustment for the composite Mayo SSIGN score. Conclusions: Both the TCGA and the ccA/ccB subtypes are associated with overall survival after adjusting for the Mayo SSIGN score. However, the effect sizes are similar to what has been reported for single markers, and thus the clinical use and cost-effectiveness of these RNA-based whole-genome signatures are questionable.

Original languageEnglish (US)
Pages (from-to)68e17-68e23
JournalUrologic Oncology: Seminars and Original Investigations
Volume33
Issue number2
DOIs
StatePublished - Feb 1 2015

Fingerprint

Renal Cell Carcinoma
Atlases
Genome
RNA
Necrosis
Neoplasms
Survival
Proportional Hazards Models
Cost-Benefit Analysis
Biomarkers
Genes

Keywords

  • Molecular subtype
  • Renal cell carcinoma
  • Survival

ASJC Scopus subject areas

  • Oncology
  • Urology

Cite this

@article{41f50f3e1ac742738d386fa6738a616d,
title = "Assessing the clinical use of clear cell renal cell carcinoma molecular subtypes identified by RNA expression analysis1These authors contributed equally to the writing of this article.",
abstract = "Objectives: To evaluate the clinical use of recently published RNA-based molecular subtyping algorithms. Patients who undergo surgery for clinically localized clear cell renal cell carcinoma can experience very different outcomes, representing a longstanding challenge for the practicing urologist. Two recent publications suggest that molecular subtyping based on the expression of large panels of genes can help clinically localized clear cell renal cell carcinoma prognostication; however, the analyses was not adjusted for routinely collected clinicopathologic indices. Methods and materials: We obtained level 3 RNA-seq RPKM data and corresponding clinicopathologic features from The Cancer Genome Atlas (TCGA) and assigned patients to the TCGA subtypes as well as to the ccA/ccB subtypes. To determine the prognostic ability of molecular subtyping after adjusting for variables that are collected as routine medical care, we used Cox models and adjusted for the composite Mayo stage, size, grade, and necrosis (SSIGN) score. Results: Both the TCGA and the ccA/ccB subtypes are significantly associated with tumor size, category, grade, and presence of necrosis. The association of these subtypes with overall survival is markedly attenuated following adjustment for the composite Mayo SSIGN score. Conclusions: Both the TCGA and the ccA/ccB subtypes are associated with overall survival after adjusting for the Mayo SSIGN score. However, the effect sizes are similar to what has been reported for single markers, and thus the clinical use and cost-effectiveness of these RNA-based whole-genome signatures are questionable.",
keywords = "Molecular subtype, Renal cell carcinoma, Survival",
author = "Eckel-Passow, {Jeanette E} and Igel, {Daniel A.} and Serie, {Daniel J.} and Joseph, {Richard W} and Ho, {Thai H} and Cheville, {John C.} and Alexander Parker",
year = "2015",
month = "2",
day = "1",
doi = "10.1016/j.urolonc.2014.07.019",
language = "English (US)",
volume = "33",
pages = "68e17--68e23",
journal = "Urologic Oncology",
issn = "1078-1439",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Assessing the clinical use of clear cell renal cell carcinoma molecular subtypes identified by RNA expression analysis1These authors contributed equally to the writing of this article.

AU - Eckel-Passow, Jeanette E

AU - Igel, Daniel A.

AU - Serie, Daniel J.

AU - Joseph, Richard W

AU - Ho, Thai H

AU - Cheville, John C.

AU - Parker, Alexander

PY - 2015/2/1

Y1 - 2015/2/1

N2 - Objectives: To evaluate the clinical use of recently published RNA-based molecular subtyping algorithms. Patients who undergo surgery for clinically localized clear cell renal cell carcinoma can experience very different outcomes, representing a longstanding challenge for the practicing urologist. Two recent publications suggest that molecular subtyping based on the expression of large panels of genes can help clinically localized clear cell renal cell carcinoma prognostication; however, the analyses was not adjusted for routinely collected clinicopathologic indices. Methods and materials: We obtained level 3 RNA-seq RPKM data and corresponding clinicopathologic features from The Cancer Genome Atlas (TCGA) and assigned patients to the TCGA subtypes as well as to the ccA/ccB subtypes. To determine the prognostic ability of molecular subtyping after adjusting for variables that are collected as routine medical care, we used Cox models and adjusted for the composite Mayo stage, size, grade, and necrosis (SSIGN) score. Results: Both the TCGA and the ccA/ccB subtypes are significantly associated with tumor size, category, grade, and presence of necrosis. The association of these subtypes with overall survival is markedly attenuated following adjustment for the composite Mayo SSIGN score. Conclusions: Both the TCGA and the ccA/ccB subtypes are associated with overall survival after adjusting for the Mayo SSIGN score. However, the effect sizes are similar to what has been reported for single markers, and thus the clinical use and cost-effectiveness of these RNA-based whole-genome signatures are questionable.

AB - Objectives: To evaluate the clinical use of recently published RNA-based molecular subtyping algorithms. Patients who undergo surgery for clinically localized clear cell renal cell carcinoma can experience very different outcomes, representing a longstanding challenge for the practicing urologist. Two recent publications suggest that molecular subtyping based on the expression of large panels of genes can help clinically localized clear cell renal cell carcinoma prognostication; however, the analyses was not adjusted for routinely collected clinicopathologic indices. Methods and materials: We obtained level 3 RNA-seq RPKM data and corresponding clinicopathologic features from The Cancer Genome Atlas (TCGA) and assigned patients to the TCGA subtypes as well as to the ccA/ccB subtypes. To determine the prognostic ability of molecular subtyping after adjusting for variables that are collected as routine medical care, we used Cox models and adjusted for the composite Mayo stage, size, grade, and necrosis (SSIGN) score. Results: Both the TCGA and the ccA/ccB subtypes are significantly associated with tumor size, category, grade, and presence of necrosis. The association of these subtypes with overall survival is markedly attenuated following adjustment for the composite Mayo SSIGN score. Conclusions: Both the TCGA and the ccA/ccB subtypes are associated with overall survival after adjusting for the Mayo SSIGN score. However, the effect sizes are similar to what has been reported for single markers, and thus the clinical use and cost-effectiveness of these RNA-based whole-genome signatures are questionable.

KW - Molecular subtype

KW - Renal cell carcinoma

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=84923367084&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84923367084&partnerID=8YFLogxK

U2 - 10.1016/j.urolonc.2014.07.019

DO - 10.1016/j.urolonc.2014.07.019

M3 - Article

VL - 33

SP - 68e17-68e23

JO - Urologic Oncology

JF - Urologic Oncology

SN - 1078-1439

IS - 2

ER -